期刊文献+

肾素-血管紧张素系统在高血压发病机制及药物治疗中的作用 被引量:4

Role of RAS in the Pathogenesis of Hypertension and Development of Antihypertensive Drugs
下载PDF
导出
摘要 探讨了肾素-血管紧张素系统在高血压发病机制中的重要作用,并依据肾素-血管紧张素系统的作用机理,从药物的分类、作用靶点、作用机理、不良反应、最新研究进展及发展前景等几个方面对以该系统为靶向目标的新型抗高血压药物进行了综述。 The pathogenesis of hypertension is very intricate and several kinds of antihypertensive drugs can control the blood pressure by modulating some systems in the body. Research show that the rennin-angiotensin system(RAS) plays an important role in the pathogenesis of hypertension. Besides, the antihypertensive drugs that take the RAS as the target are discussed in this paper from aspects such as the categories of some new drugs, modulating mechanism, adverse reaction and the development, etc.
作者 孙海燕
出处 《深圳职业技术学院学报》 CAS 2005年第2期43-47,共5页 Journal of Shenzhen Polytechnic
关键词 高血压 肾素-血管紧张素系统 抗高血压药物 hypertension rennin-angiotensinsystem antihypertensive drugs
  • 相关文献

参考文献18

  • 1[1]Johnston C I, Risvanis J. Preclinical pharmacology of angiotensin Ⅱ receptor antagonists: Update and outstanding issues[J]. Am J Hypertens, 1997,10(12 Pt 2):306-10.
  • 2[2]Unger T, Culman J, Gohlke P. Angiotensin Ⅱ receptor blockade and end-organ protection: Pharmacological rationale and evidence[J]. J Hypertens, 1998,16(Suppl7):3-9.
  • 3[3]Glassman H N, Kleinert H D, Boger R S, et al. Clinical pharmacology of Enalkiren, a novel dipeptide renin inhibitor[J]. J Cardiovasc Pharmacol, 1991,16(Supp l4):576.
  • 4[4]Clozel J P, Fischli W. Comparative effects of three diff- erent potent renin inhibitiors in primates[J]. Hypertension, 1993,22:9.
  • 5[5]Ryal M J, Hicks G W, Batley B L, et al. Effects of an orally active renin inhibitor CI-992 on blood pressure in normotensive and hypertensive monkeys[J]. J Pharmakkcol Exp Ther, 1995,268:372.
  • 6[6]Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin Ⅱ suppression in humans by the orally active renin inhibitor aliskiren(SPP100)[J]. Curr Hypertens Rep, 2002,4(4):269-270.
  • 7[7]Phillips K A, Veenstra D L, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review[J]. JAMA, 2001,286(18):2270-2279.
  • 8[8]ANNE P L, PAIVI K, KATI P, et al. Angiotensin Ⅰ-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides[J]. J Dairy Res, 2000,67:53-64.
  • 9[9]Nelson E, Merril I D, Sweet C, et al. Efficacy and safety of oral MK-954(DpU753), an angiotensin antagonist, in essential hypertension[J]. J hypertens, 1991,9(Suppl6):468.
  • 10[10]Criscione L, de Gasparo M, Buehlmayer P, et al. Pharmacological profile of volsatan[J].Br J Pharmacol, 1993,110:761.

共引文献6

同被引文献59

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部